Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Meta Expands AI Training With Employee Activity Tracking Tools 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
 - EconoTimes)
NEW YORK, March 04, 2016 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against PTC Therapeutics (“PTC” or the “Company”) (Nasdaq:PTC) in the United States District Court for the District of New Jersey on behalf of a class consisting of all persons or entities who purchased PTC securities between May 6, 2014 and February 23, 2016, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that during the Class Period, Defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects and that as a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period. According to the Complaint, on February 23, 2016, PTC announced that it received a Refuse to File letter from the United States Food and Drug Administration (“FDA”) regarding PTC’s New Drug Application (“NDA”) for Translarna™ (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”). The FDA stated in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review.
On this news, shares of PTC plummeted over 61%, closing at $10.84 per share on February 23, 2016, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than May 2, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
